15 cutting-edge research projects
The VAGABOND ITN will focus on 15 cutting-edge research projects studying molecular, epigenetic and immunological targets. All projects will (partly) include target identification, in vitro and in vivo validation, compound testing and preparation for clinical implementation. This consortium will highly stimulate international education and multi-disciplinary exchange of expertise in the different steps of pre-clinical drug development. This setting provides an opportunity for a unique European training network in which PhD students are equipped with a broad knowledge in pre-clinical drug development.
Join a generation of uniquely trained researchers
This network will be sustainable embedded in the ITCC (Innovative Treatments for Children with Cancer) Consortium. The successful candidates will be hosted by a member of a European Consortium of universities, research institutions and companies in the Netherlands, Belgium, Germany, United Kingdom, Italy, Austria, Switzerland and France. Through this network PhD students will gain access to other leading academic research groups, specialised multi-sectoral companies and the most innovative techniques and insights in the complexity of translational medicine to prepare them for future challenges in their career pathway. In this collaboration we will increase the commune expertise on tumour types and technical expertise for target validation. This will improve the implementation of interventions across paediatric cancer and strongly reduce the timeline from bench to the bedside.